

Content available at: <https://www.ipinnovative.com/open-access-journals>

IP International Journal of Medical Microbiology and Tropical Diseases

Journal homepage: <https://www.ijmmt.org/>

## Review Article

## Drug-target genes and their spontaneous mutations associated with resistance to first-line, second-line, third-line, novel and repurposed anti-tuberculosis drugs in *Mycobacterium tuberculosis* resistant strains

David Kajoba Mumena<sup>1,\*</sup>, Geoffrey Kwenda<sup>2</sup>, Caroline Wangari Ngugi<sup>3</sup>, Andrew Kimang'a Nyerere<sup>4</sup>

<sup>1</sup>Dept. of Medical Microbiology, Faculty of Biomedical Sciences, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

<sup>2</sup>Dept. of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka, Zambia

<sup>3</sup>Dept. of Medical Microbiology, Faculty of Biomedical Sciences, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

<sup>4</sup>Dept. of Medical Microbiology, Faculty of Biomedical Sciences, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya



## ARTICLE INFO

## Article history:

Received 15-06-2022

Accepted 18-07-2022

Available online 06-09-2022

## Keywords:

Drug-target genes

Drug-resistant tuberculosis

First-line anti-TB drugs

Fluoroquinolones

Mutations

Mycobacterium tuberculosis

Novel anti-TB drugs

Repurposed anti-TB drugs

Second-line injectable drugs

## ABSTRACT

Drug-resistant tuberculosis is a threat to the control of tuberculosis globally, it develops mainly due to mutations in target genes of *Mycobacterium tuberculosis* (MTB). Mutations in the *rpoB* gene confer resistance to rifampicin (RIF). The most frequent mutations conferring resistance to RIF include; Ser531Leu, Asp516Val, and His526Asp. Isoniazid resistance (INHr) occur most frequently due to mutations in the *katG*, *inhA* and its promoter. Most frequent mutation in *katG* is Ser315Thr 1, while in *inhA* include; Thr8Cys, Ala16Gly, and Cys15Thr. Mutations in *emba*, *embB*, *embC*, *embR*, *ubia*, *aftA*, and *iniA* genes confer resistance to ethambutol. 70% of mutations in the *embB* gene occur in codon 306, 406, or 497 and include; Met306Leu, Gly43Cys, and Ser412Pro. Mutations in the *pncA*, *panD*, *clpC1*, and *Rv2783c* genes mediate resistance to pyrazinamide. Frequent mutations in *pncA* include; Tyr64Ser, Phe94Ala, and Trp68Gly. MTB resistance to streptomycin (STR) occur due to mutations in the *rrs*, *gidB*, and *rpsL* genes. Mutations *rrs* (Ala80Pro), and *rpsL* (Lys43Arg) confer resistance to STR. Fluoroquinolone resistance is mediated via mutations in the *gyrA* and *gyrB* genes. The most common mutations in the *gyrA* gene include; Gly88Cys, Ala90Val, and Ser91Pro. While those in the *gyrB* gene include; Glu540Val, and Asn538Asp. Mutations in the *rrs* and *eis* promoter region cause resistance to the kanamycin and amikacin. While mutations in the *rrs* and *thyA* cause resistance to capreomycin and viomycin. Common mutations in *rrs* include; Cys1402Thr, Ala1401Gly, and Gly1484Thr. While mutations in the *eis* include; Cys12Thr, Gly10Ala, and Gly37Thr. Detection of drug-target genes and their mutations has therapeutic and diagnostic value.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

## 1. Introduction

Tuberculosis (TB) is a global public health emergency.<sup>1,2</sup> It causes high mortality and morbidity rates, it kills one

person every 21 seconds.<sup>3,4</sup> TB is caused by species of the *Mycobacterium tuberculosis* complex (MTBC), some of which are adapted to humans (*Mycobacterium tuberculosis* [MTB] and *Mycobacterium africanum*), while others to animals (*Mycobacterium bovis*, *Mycobacterium*

\* Corresponding author.

E-mail address: [davidmumena@gmail.com](mailto:davidmumena@gmail.com) (D. K. Mumena).

*microti*, *Mycobacterium pinnipedii*, *Mycobacterium mungi*, and *Mycobacterium caprae*), and others are smooth bacilli (*Mycobacterium canettii*).<sup>5–7</sup> MTB is the major causative pathogen for human TB among the species of MTBC, as it causes 97–99% of all TB cases globally.<sup>3</sup>

TB is the second leading cause of death from a single infectious agent, after coronavirus disease 2019 (COVID-19), a highly infectious disease caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).<sup>8,9</sup> The current TB morality is severely impacted by COVID-19 and not HIV/AIDS. COVID-19 has reversed years of progress made in the fight against TB. Globally TB targets have gone off-track and many years of progress reversed.<sup>9</sup> The burden of TB is driven by the emergence and spreading of drug-resistant MTB strains.<sup>2,4,10</sup> TB-HIV co-infection has led to an increase in different types of drug-resistant TB.<sup>11</sup>

The latest World Health Organization Global TB Report of 2021 revealed that 132,222 cases of multidrug-resistant/rifampicin resistant tuberculosis (MDR/RR-TB) and 25,681 of pre-extensively drug-resistant/extensively drug-resistant tuberculosis (pre-XDR/XDR-TB) were detected in 2020.<sup>9</sup> The global prevalence of MDR/RR-TB stood at 3.5% and 18% among the new TB cases and previously treated cases respectively.<sup>9</sup> In 2019, 206,030 cases of MDR/RR-TB were detected and notified globally.<sup>12</sup> This meant the global prevalence of MDR/RR-TB was 3.3% among the new TB cases and 17.7% among the previously treated cases.<sup>12,13</sup> In 2018, 186,772 cases of MDR/RR-TB were detected and notified globally.<sup>14</sup> The global prevalence of MDR/RR-TB was 3.4% and 18% among the new TB cases and previously treated TB cases respectively.<sup>14</sup> In 2017, 160,684 cases of MDR/RR-TB were detected and notified globally.<sup>15</sup> The global prevalence of MDR/RR-TB was 3.5% among the new TB cases and 18% among the previously treated TB cases, in 2017.<sup>15</sup> An estimated 8.5% of MDR-TB cases were estimated to have XDR-TB in 2017. In 2016, 153,119 cases of MDR/RR-TB were detected and notified globally.<sup>16</sup> The global prevalence of MDR/RR-TB was 4.1% and 19% among the new TB cases and previously treated TB cases respectively, in 2016.<sup>16</sup>

Drug-resistant tuberculosis (DR-TB) is jeopardizing efforts in the control and prevention of TB.<sup>2</sup> DR-TB can be transmitted through the air from one person to another or can develop when MTB strains become resistant to anti-TB drugs due to a number of factors which include: poor adherence, poor compliance, poor selection of regimens, low efficacy anti-TB drugs, late diagnosis, interrupted supply, stock-outs, spontaneous mutations, and chromosomal replication errors.<sup>3,10,17–21</sup> Different categories of DR-TB have been defined and they include; multidrug-resistant tuberculosis (MDR-TB), pre-extensively drug-resistant tuberculosis (Pre-XDR-

TB), extensively drug-resistant tuberculosis (XDR-TB), extremely drug-resistant tuberculosis (XXDR-TB), and totally drug-resistant tuberculosis (TDR-TB).<sup>4,5,22</sup>

MDR-TB is TB resistant to at least rifampicin (RIF) and isoniazid (INH).<sup>23,24</sup> Pre-XDR TB is TB resistant to RIF, INH, plus any one fluoroquinolone (FLQ) (levofloxacin, moxifloxacin, ofloxacin, or gatifloxacin), or any one of the second-line injectable drugs (SLIDs) (kanamycin, capreomycin, or amikacin).<sup>3</sup> XDR-TB is TB resistant to RIF, INH, plus any FLQs, plus any SLIDs.<sup>10</sup> XXDR-TB is a type of TB characterized by the presence of MTB isolates that show in-vitro resistance to all first- and second-line anti-TB drugs tested.<sup>4,25,26</sup> TDR-TB is TB characterized by MTB isolates that show resistance to all tested antibiotics plus some that are currently in the discovery pipeline.<sup>4,27</sup>

Mutations in target genes or their promoter regions of genes are associated with resistance to anti-TB drugs.<sup>22</sup> Resistance to first-line anti-TB drugs is mainly caused by mutations in the following genes: *rpoB* gene for resistance to rifampicin; *inhA*, *kasA*, *ahpC*, *katG* and *ndh* genes for resistance to isoniazid; *embB* gene for resistance to ethambutol; and finally, the *pncA*, *panD*, *rpsA*, *clpC1*, and *Rv2783c* genes for resistance to pyrazinamide.<sup>28,29</sup> While resistance to second-line anti-TB drugs is mainly caused by mutations in the following genes: *rpsL*, *rrs* and *gidB* genes for resistance to streptomycin; *gyrA* and *gyrB* genes for resistance to the fluoroquinolones; *rrs*, *eis* and *tlyA* genes for resistance to the aminoglycosides and cyclic polypeptide antibiotics.<sup>29,30</sup>

The aim of this comprehensive mini-review was to highlight molecular targets and their mutations associated with drug-resistance to first-line, second-line, novel and repurposed anti-tuberculosis drugs in resistant MTB clinical isolates. The identification of drug-target genes with their spontaneous mutations helps in designing new drugs or improving the efficacy of the available drugs as well as help in providing vital information for designing new molecular diagnostic assays for rapid detection of DR-TB.

## 2. Mechanisms for Drug-Resistance to First-Line Anti-Tuberculosis Drugs

First-line anti-TB drugs used are rifampicin, isoniazid, pyrazinamide and ethambutol.<sup>31</sup> MTB resistance to each one of the first-line anti-TB drugs has been detected in TB patients. MTB resistance is attributed to a number of factors some of which include: the mycolic acid, lipid layer of the cell wall, presence of  $\beta$ -lactamase enzymes, presence of efflux pumps, and the development of mutations in the target genes of MTB.<sup>32</sup> The mycolic acid, lipid layer of MTB makes the cell wall to become less permeable to a number of anti-TB drugs.<sup>33</sup> The efflux pumps play a role of pumping several antimicrobial agents out of the cells of MTB.<sup>33,34</sup> The  $\beta$ -lactamase enzyme of MTB inactivates the  $\beta$ -lactam antibiotics thus causes resistance to this class

of antibiotics.<sup>33</sup> The development of mutations in the target genes of MTB is a major mechanism through which resistance to anti-TB drugs occurs.<sup>35,36</sup>

### 3. Drug Target Genes and Mutations Conferring Resistance to Isoniazid

Isoniazid resistance is brought about by mutations in several genes of *M. tuberculosis* such as the *katG*, *inhA*, *ahpC*, *kasA*, *oxyR*, *furA*, *fabG1-inhA*, and *ndh* genes.<sup>3,34,37</sup> However, Current research has shown that resistance to isoniazid can also be caused by an upregulation of efflux pumps or isoniazid inactivators.<sup>38,39</sup> Mutations in the *katG*, *inhA* and its promoter, and the *oxyR-ahpC* intergenic region frequently confer resistance to INH.<sup>3,22,29</sup> While mutations in the following genes *oxyR*, *furA*, *ndh*, *ahpC*, *kasA*, and *fabG1-inhA* infrequently confer resistance to INH.<sup>3,34</sup> Recent studies have also found that mutations in the *dfrA* gene cause resistance to isoniazid.<sup>29</sup> Mutations in the *inhA* gene cause resistance to both isoniazid and ethionamide which share the same binding site on the promoter region.<sup>40</sup> The most frequently identified mutation in the *katG* gene is the Ser315Thr1, which confer a high-level resistance to INH.<sup>3,23,29</sup> While that in the *inhA* gene is the C-15T, which confer low-level resistance to INH.<sup>3</sup> The two mutations *katG* MUT (Ser315Thr1) and *inhA* MUT (C-15T) account for 80% of resistance to INH.<sup>34,41</sup> The four most frequently identified mutations in the *inhA* gene that are associated with resistance to INH are Cys15Thr, Thr8Cys, Thr8Ala, and Ala16Gly.<sup>3,42</sup> Isoniazid resistance that is associated with mutations in the *katG* gene occurs before rifampicin resistance.<sup>29</sup> Mutations in the *katG* gene can therefore, serve as a key marker for pre-MDR TB.<sup>43</sup>

### 4. Drug Target Genes and Mutations Conferring Resistance to Rifampicin

Mutations within a hypervariable region of the *rpoB* gene, which codes for the  $\beta$ -subunit RNA polymerase confer resistance to RIF in 95% of MTB clinical isolates.<sup>22,44–47</sup> About 96% of RIF- resistance occurs within the rifampicin resistance determining region (RRDR) which is also called the “hot-spot region” (HSR-*rpoB*), covering codons 507–533 of the *rpoB* gene.<sup>22</sup> Mutations at codons 531, 526, and 516 in the *rpoB* gene are the most commonly identified in RIF-resistant MTB isolates.<sup>22</sup> Mutations at codons 529, 526, 518, and 516 confer low-level resistance to RIF, whereas mutations at codons 526–531 show the highest frequency and are associated with a high-level resistance to RIF.<sup>22,23</sup> Mutations at codon 531 is associated with cross-resistance to rifabutin.<sup>22</sup> The most frequent mutations associated with resistance to RIF in the *rpoB* gene are Ser531Leu, His526Asp, His526Tyr, and Asp516Val.<sup>23,42</sup> These point mutations involve changes in the positions of amino acids, and can be an insertion, deletion, or

missense.<sup>45,48</sup>

### 5. Drug Target Genes and Mutations Conferring Resistance to Ethambutol

Mutations in genes that confer resistance to ethambutol (EMB), occur in specific regions known as ethambutol resistance-determining regions (ERDR) or “hot-spot regions” (HSR).<sup>49</sup> EMB resistance in *M. tuberculosis* is caused by mutations in the following genes: *embA*, *embB*, *embC*, *embR*, *UbiA*, *aftA*, and *iniA* genes.<sup>5,22,29,50</sup> The most common mechanism for resistance to ethambutol is mutation in the *embB* gene, occurring at codon 306.<sup>29</sup> Mutations at codon 406 and 497 within the *embB* gene have also been detected.<sup>51</sup> For example the mutations Met306Leu and Met306Val at codon 306 in the *embB* gene are associated with resistance to EMB.<sup>22</sup> Novel mutations *embB* Gly43Cys, *embB* Gly554Asn, and *embB* Ser412Pro in the *embB* gene also confer resistance to EMB.<sup>5</sup> Mutations in the *ubiA* gene in-conjunction with mutations in the *embB* gene have been found to cause a high-level resistance to ethambutol.<sup>22,52</sup> Studies have also shown that the high-level resistance to ethambutol develop via a stepwise acquisition of mutations in the *embB*, *ubiA*, and *embC* genes.<sup>53</sup> From the total of 98% of mutations that occur in the *embB* CAB locus of the *embB* gene in resistant MTB isolates, 70% are found in codon 306, 406, or 497, while 13% of the mutations are found out side of the three regions between condons 296 and 426, and 15% are in the *embC-embA* intergenic region.<sup>22</sup> The *embCAB* operon comprises of three genes *embA*, *embB*, and *embC*. Therefore, mutations in this operon are associated with resistance to EMB.<sup>51</sup>

### 6. Drug Target Genes and Mutations Conferring Resistance to Pyrazinamide

Mutations in the *pncA*, *panD*, *rpsA*, *clpC1*(Rv3596c), and Rv2783c genes of MTB confer resistance to pyranamide (PZA).<sup>22,29,40,54</sup> However, mutations in the *pncA* and its promoter region are the most frequently identified as they account for 72–99% of resistance to PZA.<sup>22,54</sup> The most frequent mutations in the *pncA* gene are: Asp49Asn, Tyr64Ser, Trp68Gly, and Phe94Ala.<sup>54</sup> Studies have also shown that PZA resistance is strongly associated with rifampicin resistance. This finding confirms that the burden of PZA resistance is in patients who have rifampicin resistance.<sup>29</sup>

### 7. Drug Target Genes and Mutations Conferring Resistance to Second-Line Anti-Tuberculosis Drugs

The second-line drugs are key in the management of drug-resistant TB, and they include: fluoroquinolones, aminoglycosides, streptomycin, cycloserine, ethionamide,

prothionamide, para-amino salicylic acid, and cyclic polypeptides.<sup>29,37</sup> Drug-resistance to all anti-TB drugs has been reported in some countries.<sup>55</sup> MTB resistance is mainly caused by mutations in the target genes.<sup>56</sup> Mutations in the *rpsL*, *rrs* and *gid* genes cause resistance to streptomycin, while mutations in the *gyrA* and *gyrB* genes cause resistance to the fluoroquinolones. Mutations in the *rrs*, *eis* and *tlyA* genes cause resistance to the aminoglycosides and cyclic polypeptide antibiotics.<sup>30</sup>

## 8. Drug Target Genes and Mutations Conferring Resistance to Streptomycin

Streptomycin (STR) resistance by *M. tuberculosis* is caused by mutations in the *rpsL*, *rrs*, and *gidB* genes.<sup>22,23,40</sup> The following mutations confer resistance to STR, *rpsL* (Lys43Arg, Lys88Gln, Lys88Arg, Cys117Thr), *rrs* (Cys517Thr, Ala514Cys, Ala906Gly, Ala907Cys), *gidB* (Ala183Val, Gly71Arg, Tyr22His, Gly37Arg, Pro75Ser, Gly76Asp, Ile81Thr, Phe100Leu, Val124Gly, Ala134Gly, Ala138Pro, Ser149Arg, Leu152Ser, and Gly157Arg).<sup>57</sup> Mutations in the *rpsL* and *rrs* genes are the major mechanisms that confer resistance to STR in *M. tuberculosis*, they account for 60-70% of resistance to STR.<sup>29</sup> Recent studies have revealed that mutations in the *gidB* gene cause low-level resistance and accounts for 33% of resistance to STR in clinical *M. tuberculosis* isolates.<sup>29,37,40</sup> The most frequently identified mutation in the *rpsL* gene is the replacement of lysine with arginine at position 43 and 88.<sup>22</sup> While in the *rrs* gene is the mutation Ala80Pro.<sup>22</sup> MTB strains that are resistant to STR confer cross-resistance to amikacin and kanamycin.<sup>22</sup>

## 9. Drug Target Genes and Mutations Conferring Resistance to Aminoglycosides and Cyclic Poly-Peptide Antibiotics

Aminoglycosides and the cyclic polypeptide antibiotics are second-line drugs that are used in the treatment of drug-resistant TB.<sup>29</sup> The two key aminoglycosides are kanamycin (KAN) and amikacin (AMK), while capreomycin (CAP) and viomycin (VIO) are key cyclic polypeptide antibiotics.<sup>37</sup> The three drugs kanamycin, amikacin, and capreomycin are called second-line injectable drugs.<sup>29</sup>

Mutations in the *rrs*, *eis*, *tlyA* genes result in resistance to the second-line injectable drugs.<sup>37</sup> Mutations in the *rrs* gene cause resistance to all the three second-line injectable drugs, and is the most common molecular mechanism for resistance to this class of anti-TB drugs.<sup>29</sup> Mutations in the *rrs* gene, specifically at positions 1400, 1401, and 1483 base pair (bp) are associated with a high-level resistance to both AMK and KAN in KAN-resistant MTB strains.<sup>22</sup> The mutation Ala1401Gly in the *rrs* gene confer a high-level resistance to AMK and KAN along with cross-resistance

to CAP. While the mutation Cys1402Thr or Gly1484Thr is associated with resistance to CAP and a cross-resistance to KAN or VIO.<sup>22</sup> Mutations in the *rrs* gene are also associated with resistance to CAP and VIO.<sup>34</sup> Mutations in the *eis* gene confer low-level resistance to KAN.<sup>22</sup> Mutations in the *rrs* gene accounts for about 70-80% resistance to CAP and AMK as well as 60% resistance to KAN in resistant *M. tuberculosis* isolates worldwide.<sup>29</sup> Mutations in the *eis* gene cause about 80% low-level resistance to KAN but not to AMK.<sup>29</sup> While mutations in the *tlyA* gene cause about 3% resistance to CAP.<sup>29,37</sup> Cross-resistance to streptomycin and KAN occur due to mutations in the *whiB7* gene of *M. tuberculosis*.<sup>58</sup> Mutations in the *tlyA* gene also results in resistance in both CAP and VIO.<sup>37</sup>

## 10. Drug Target Genes and Mutations Conferring Resistance to Fluoroquinolones

Fluoroquinolones (FLQs) are second-line anti-TB drugs, examples of those used in the treatment of drug-resistant TB include; levofloxacin, ofloxacin, gatifloxacin and moxifloxacin.<sup>59–61</sup>

Mutations in the quinolone resistance determining region (QRDR) of both *gyrA* and *gyrB* genes of MTB cause resistance to FLQs.<sup>3,22,29,34,40</sup> Mutations in the *gyrA* gene cause a high-level resistance to FLQs, while mutations in the *gyrB* gene cause a low-level resistance to FLQs. However, combined mutations in both the *gyrA* and *gyrB* genes result in a high-level resistance to FLQs.<sup>58</sup> The most common mutations in the *gyrA* gene are: Gly88Cys, Gly88Ala, Ala90Val, Ser91Pro, Asp94Gly, Asp94Ala, Asp94His, Asp94Asn and Asp94Tyr. While those in the *gyrB* gene are: Glu540Val, and Asn538Asp.<sup>3,22</sup> Mutations in the *gyrB* gene are not frequently found among MTB clinical isolates.<sup>22</sup> Mutations in both *gyrA* and *gyrB* genes, such as Asn538Ile (*gyrB*)-Asp94Ala (*gyrA*) and Ala543Val (*gyrB*)-Asp94Asn/Asp94Gly(*gyrA*) cause very high-resistance to FLQs.<sup>22,58</sup> Cross-resistance among the FLQs occurs.<sup>37</sup> Resistance to ofloxacin causes resistance to other FLQs.<sup>61</sup> FLQ resistance is one of the most important criteria that is used for defining extensively drug-resistant TB.<sup>62</sup>

The second mechanism through which *M. tuberculosis* develops resistance to FLQs is the use of efflux pumps.<sup>34,59</sup> These biological pumps remove the fluoroquinolone drugs out of the mycobacterial cells.<sup>59</sup>

## 11. Drug Target Genes and Mutations Conferring Resistance to Cycloserine

D-cycloserine (DCS) is a second-line drug used in the treatment of MDR-TB and XDR-TB.<sup>22,63</sup>

Resistance to cycloserine by MTB is due to mutations in the *alr*, *ddlA*, *ald* (Rv2780) and *cycA* genes.<sup>22,64,65</sup> Mutations in the *alr* gene are the main cause for resistance to cycloserine and involve three major mutations: *alr* *mtb*

Y364D, *alr<sub>mtb</sub>* R373L, and *alr<sub>mtb</sub>* M319T.<sup>63</sup> The point mutation in the *cycA* gene of *M. bovis* confer resistance to DCS.<sup>22</sup> While the over expression of *alrA* cause resistance to DCS in recombinant mutant of *M. smegmatis*.<sup>22</sup>

### 12. Drug Target Genes and Mutations Conferring Resistance to Ethionamide

Ethionamide (ETH) is a second-line drug used in the treatment of MDR-TB.<sup>66</sup> Mutations in the *ethR*, *inhA*, *ndh*, *mshA*, and *etaA/ethA* genes of MTB result in resistance to ethionamide.<sup>22,29,66</sup> Mutations in the *inhA* gene result in co-resistance to ETH and INH, because the two drugs are structural analogues of each other, share the same target and mechanism of action.<sup>29,66</sup> Mutations in the *ethA* and *ethR* genes confer resistance to ETH and prothionamide.<sup>22</sup> Mutations in *ethA/ethR* genes, coupled with mutations in the *inhA* or its promoter region confer resistance to both ETH and INH.<sup>22</sup> The mutation C-15T confer a low-level resistance to INH and a cross-resistance to ETH.<sup>67,68</sup> The mutations Ala95Thr and Phe110Leu in the *ethR* gene confer resistance to ETH.<sup>69</sup> While the mutations Ile95Pro, Ser94Ala, and Ile21Thr in the *inhA* gene confer resistance to both INH and ETH in MTB resistant clinical isolates.<sup>70</sup>

### 13. Drug Target Genes and Mutations Conferring Resistance to Prothionamide

Prothionamide (PTH) is a second-line drug used in the treatment of drug-susceptible TB meningitis, miliary TB and MDR-TB.<sup>71</sup> PTH is a structural analogue of INH. The two drugs have a common target, which is *inhA* gene.<sup>69</sup> Mutations in the *ethA*, *ethR*, *mshA*, *ndh*, *katG*, *inhA* and/or its promoter region result in resistance to PTH.<sup>69,71,72</sup> PTH resistance is most commonly caused by mutations in the *ethA* gene of MTB.<sup>71</sup> Mutations in the *inhA* and *ndh* genes result in cross-resistance to PTH, ETH, and INH.<sup>29,66,71,72</sup> Mutations in both the *ethA* and *mshA* genes result in cross-resistance to PTH and ETH.<sup>66,71,72</sup> The mutations Val152Met and Arg216Cys in the *ethR* gene confer resistance to PTH.<sup>69</sup> Mutations in the *katG* and *ethA* confer resistance to both PTH and INH, for instance *katG* (Ser315Th, Ala264Val, Thr275Ala), and *ethA* (Cys137Arg, Ser266Arg, Pro334Ala).<sup>69</sup>

### 14. Drug Target Genes and Mutations Conferring Resistance to Para-Amino Salicylic Acid

Para-amino salicylic acid (PAS) is a structural analogue of para-amino benzoic acid (PABA), it is a second-line drug used in the treatment of MDR-TB.<sup>29,73</sup> PAS improves the cure rate and reduces the emergence of drug-resistant TB.<sup>74</sup> Mutations in the *thyA*, *dfrA*, *folC*, *folP1*, *folP2*, and *ribD* genes of *M. tuberculosis* confer resistance to PAS.<sup>22,29,75,76</sup> The following mutations in the *thyA* gene confer resistance

to PAS Arg127Leu, Leu143Pro, Leu172Pro, Cys146Arg, Ala182Pro, and Val261Gly.<sup>76</sup> A study done at the Central Laboratory, Public Health Medical Centre, Chongqing, in South-western China found that resistance to PAS in MTB was mainly caused by mutations in the *thyA*, *ribD* and *folC* genes, with mutations in the *folC* gene being the most frequent.<sup>73</sup>

### 15. Drug Target Genes and Mutations Conferring Resistance to Novel and Repurposed Anti-Tuberculosis Drugs

The emergence of new resistant mechanisms by *M. tuberculosis* has led to the development of new anti-TB drugs by different pharmaceutical companies to treat drug-resistant TB cases.<sup>77</sup> Examples of new anti-TB drugs that have recently been developed include: bedaquiline (BDQ), linezolid (LZD), delamanid (DLM), pretomanid (PTM), and clofazimine (CFZ). However, drug-resistance has already been reported even to some of these newly developed drugs.<sup>29</sup>

### 16. Drug Target Genes and Mutations Conferring Resistance to Bedaquiline

Bedaquiline (BDQ) is used in combination with other anti-TB drugs for the treatment of MDR-TB.<sup>78</sup> Mutations in the *atpE* (Rv1305), *pepQ* (Rv2535c), and *mmpR* (Rv0678), Rv1979c genes of MTB confer resistance to BDQ.<sup>29,79</sup> Mutations in the *atpE* gene cause a high-level resistance to BDQ with the most frequently identified mutations being Ala63Pro and Ile66Met.<sup>22,29,34,80</sup> The other mutations occurring in *atpE* include Asp28Ala, Ala63Val, and Ile66Val.<sup>81</sup> Mutations in the Rv0678 gene include Gly66Glu, Met1Ala, Trp42Arg, Ser53Leu, Ser63Arg, and Ser63Gly.<sup>82</sup> Mutations in the Rv0678 gene cause an upregulation of MmpL5, a multi-substrate efflux pump, resulting to resistance not only to BDQ but also to clofazimine (CFZ).<sup>22</sup> Mutations in the Rv0678 gene cause a low-level cross resistance between BDQ and CFZ.<sup>79</sup> Similarly, mutations in the Rv2535c cause a low-level resistance to BDQ and CFZ.<sup>79</sup> Mutations in the *pepQ* gene confer cross-resistance between CLO and BDQ.<sup>22</sup>

### 17. Drug Target Genes and Mutations Conferring Resistance to Pretomanid and Delamanid

Mutations in the *ddn*, *fgd1*, *fbiA*, *fbiB*, *fbiC*, *fbiD*, and *MmpS5-MmpL5* genes result in resistance to pretomanid (PTM) or delamanid (DLM).<sup>22,29,81,83,84</sup> Mutations in the *fbiA* and *fgd1* genes of *M. tuberculosis* result in resistance to DLM.<sup>29</sup> Mutations in the *fgd1* occur between codons 43 and 230, for Pro43Arg example.<sup>81</sup> Cross-resistance between the drugs, PTM and DLM has been reported. This cross-resistance is inevitable

because the two drugs have a similar chemical structure.<sup>80</sup> The following mutations ddn (Asp113Asn, Arg72Trp, Gly34Arg, Gly81Ser, Pro131Leu, Pro45Leu, Met1Thr, Trp88Arg, Tyr65Ser, Leu49Pro, Leu107Pro, Gly81Asp, and Gly53Asp), *fgd1* (Thr960Cys, Arg64Ser, Gln88Glu, Lys270Met, Lys296Glu, Lys296Arg, Arg247Trp, and Met93Ile), *fbtA* (Lys2Glu, Ile280Val, Ile209Val, Ser126Pro, Arg304Gln, Arg175His, Asp49Tyr, Gly139Arg, Ala178Thr, and Asp49Thr), *fbtB* (Lys448Arg, Ala31Thr, Asp90Asn, Arg265Gln, Val348Ile, Gly325Ser, Pro182Leu, Pro361Ala, and Leu326Phe), *fbtC* (Val318Ile, Cys105Arg, Leu228Phe, Leu377Pro, Ala856Pro, Ala835Val, Ser762Asn, Ala416Val, Trp678Gly, Thr273Ala, Trp678Gly, Ile128Val, Gly655Ser, and Thr455Ala) confer resistance to DLM or PTM.<sup>81,84,85</sup> The three non-synonymous single nucleotide polymorphisms (SNPs), Gly84Val, Ala175Thr, and Met221Arg in the *ndh* gene of *Mycobacterium smegmatis* confer resistance to DLM, but not in *M. tuberculosis*.<sup>84</sup>

### 18. Drug Target Genes and Mutations Conferring Resistance to Linezolid

Linezolid (LZD) is used in combination with other anti-TB drugs for the treatment of complicated cases of MDR-TB and XDR-TB.<sup>86</sup> Mutations in the *rhl* and *rplC* genes of *M. tuberculosis* confer resistance to both LZD and sutezolid (SZD).<sup>22,29,87</sup> The following mutations *rhl* (Ala2810Cys, Gly2299Thr, Gly2814Thr, Gly2270Thr, Gly2270Cys, and Gly2746Ala), and *rplC* (Cys154Arg, Thr460Cys, Ala328Gly, and Cys154Arg) confer resistance to LZD.<sup>22,81,88,89</sup> Mutations in the *rplC* gene are associated with higher minimum inhibitory concentration (MIC) values to LZD, while those in *rhl* gene are associated with lower MIC values.<sup>89</sup> Mutations in the *rhl* gene cause a high-level resistance to LZD.<sup>29,87</sup>

### 19. Drug Target Genes and Mutations Conferring Resistance to Clofazimine

Clofazimine (CFZ) is used in combination with other anti-TB drugs for the treatment of drug-resistant TB.<sup>90</sup> Resistance to CFZ by *M. tuberculosis* is attributed to mutations in the Rv0678, Rv1979c, Rv2535c, *ndh* and *pepQ* genes.<sup>29,88</sup> The following mutations Rv0678 (Val85Phe, Arg31Ser, Gly65Ala, Ala86Val, Arg109Pro, Gln131His, Val20Phe, Cys46Tyr, Ala36Val, Thr33Asn, Leu43Arg, Gln51Arg, Ser68Gly, Ala59Val, Ser53Leu, Gly65Glu, Ser63Asn, Ala84Glu, Glu66Val, Arg90Pro, Arg89Leu, Ala102Val, Leu114Pro, Ala102Thr, Leu122Pro, and Val351Ala), *pepQ* (Leu145Ile), Rv1979c (Val351Ala), and Rv2535 (Glu89\*- a stop codon mutation) confer resistance to CFZ.<sup>56,91</sup> The major mechanism for resistance to CFZ is due to mutations in the Rv0678 gene.<sup>91</sup> Cross-resistance between the drugs CFZ and bedaquiline has been reported and is actually due to mutations in the Rv0678 and *pepQ* genes as well as to an up regulation in the *MmpL5*

efflux pump in *M. tuberculosis*.<sup>29,92</sup>

### 20. Drug Target Genes and Mutations Conferring Resistance to Ethylenediamine

The drug 1,2-ethylenediamine (SQ-109) is derived from ethambutol pharmacophore. SQ-109 inhibits cell wall biosynthesis by blocking *MmpL3* (Mycobacterial membrane proteins large 3).<sup>93</sup> It is effective against MTB clinical isolates that are resistant to ethambutol.<sup>93</sup> *MmpL3* performs a vital role in cell wall biosynthesis in MTB, as it helps in transporting trehalose mono-mycolates (TMMs) across the cell envelop/inner membrane for subsequent incorporation into trehalose di-mycolates (TDMs) or arabinogalactan during cell wall biosynthesis in MTB.<sup>82,94</sup> Mutations in the *MmpL3* gene of resistant MTB clinical isolates cause resistance SQ-109. While an up-regulation of the *ahpC* gene causes resistance to SQ-109, EMB, and INH.<sup>22</sup> Mutations in the *MmpL3* gene include Val285Ala, Leu567Pro, Val646Met, Met649Thr, Ala700Thr, Leu567Pro, and Gln40Arg.<sup>82,94</sup>

### 21. Conclusion

Drug-resistant TB (MDR-TB, pre-XDR-TB, XDR-TB, XXDR-TB, and TDR-TB) is one of the major public health crises, causing high mortality rates globally, and is hampering efforts in the control of TB. DR-TB has worsened due to the COVID-19 pandemic, which has reversed years of progress made in the fight against TB. DR-TB is mainly caused by spontaneous mutations in genes that code for drug converting enzymes or drug-targets. Identification of drug-target genes with their spontaneous mutations helps in designing new drugs or improving the efficacy of the available drugs as well as help in providing vital information for designing new molecular diagnostic assays for rapid detection of DR-TB. Indeed, drug-target genes with their mutations offer therapeutic and diagnostic value.

### 22. Conflict of Interest

The authors declare no conflict of interest with regards to the publication of this research review article.

### 23. Source of Funding

None.

### References

1. Zong K, Luo C, Zhou H, Jiang Y, Li S. Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis. *BMC Microbiol J.* 2019;19(177):1–21. doi:10.1186/s12866-019-1516-5.
2. Welekidan LN, Skjerve E, Dejene TA, Gebremichael MW, Brynildsrud O. Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia:


- A cross-sectional study. *PLoS ONE*. 2020;15(8):1–20. doi:10.1371/journal.pone.0236362.
3. Mumena DK, Kwenda G, Ngugi CW, Nyerere AK. Molecular Detection of Drug-Resistant Mycobacterium tuberculosis in Sputum Specimens from the New and Previously Treated Tuberculosis Cases at the National Reference Chest Diseases Laboratory in Lusaka, Zambia. *J Biomed Res Environ Sci*. 2021;2(4):232–43. doi:10.37871/jbres1218.
  4. Allué-Guardia A, García JJ, Torrelles JB. Evolution of Drug-Resistant Mycobacterium tuberculosis strains and their adaptation to the Human lung environment. *Front Microbiol*. 2021;12:612675. doi:10.3389/fmicb.2021.612675.
  5. Al-Saeedi M, Al-Hajoj S. Diversity and evolution of drug-resistance mechanisms in Mycobacterium tuberculosis. *J Infect Drug Resist*. 2017;10:333–42. doi:10.2147/IDR.S144446.
  6. Senghore M, Diarra B, Gehre F, Out J, Worwui A, Muhammad AK, et al. Evolution of Mycobacterium tuberculosis complex lineages and their role in an emerging threat of multidrug-resistant tuberculosis in Bamako, Mali. *Nat Scientific Rep*. 2020;10(327):1–9. doi:10.1038/s41598-019-56001-0.
  7. Khoshnood S, Taki E, Sadeghifard N, Kaviar VH. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis Structure of Drug. *Front Microbiol*. 2021;12:717045. doi:10.3389/fmicb.2021.717045.
  8. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *The New England Journal of Medicine*. 2020;383(27):2603–2615.
  9. World Health Organization (WHO). Global Tuberculosis Report 2021. World Health Organization. Geneva, Switzerland: World Health Organization ; 2021. Available from: <https://apps.who.int/iris>.
  10. Chisompola NK, Streicher EM, Miriam C, Muchemwa K, Warren RM, Sampson SL, et al. Molecular epidemiology of drug-resistant Mycobacterium tuberculosis in Africa: a systematic review. *BMC Infect Dis*. 2020;20(344). doi:10.1186/s12879-020-05031-5.
  11. Swain SS, Sharma D, Hussain T, Pati S. Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis. *Emerg Microbes Infect*. 2020;9(1):1652–63. doi:10.1080/22221751.2020.1785334.
  12. World Health Organization (WHO). Global Tuberculosis Report 2020. Geneva, Switzerland: World Health Organization ; 2020. Available from: <https://apps.who.int/iris>.
  13. Santos FLD, Souza L, Bruce ATI, Crispim JDA, Arroyo LH, Ramos ACV, et al. Patients' perceptions regarding multidrug-resistant tuberculosis and barriers to seeking care in a priority city in Brazil during COVID-19 pandemic: A qualitative study. *PLoS ONE*. 2021;16(4):1–19. doi:10.1371/journal.pone.0249822.
  14. World Health Organization (WHO). Global Tuberculosis Report 2019. Geneva, Switzerland: World Health Organization ; 2019. Available from: <https://apps.who.int/iris>.
  15. World Health Organization (WHO). Global Tuberculosis Report 2018. Geneva, Switzerland: World Health Organization; 2018.
  16. World Health Organization (WHO). Global Tuberculosis Report 2017. Geneva, Switzerland: World Health Organization; 2017. Available from: <https://apps.who.int/iris>.
  17. Seyoum B, Demissie M, Worku A, Bekele S, Aseffa A. Prevalence and Drug-resistance patterns of Mycobacterium tuberculosis among new smear positive pulmonary tuberculosis patients in Eastern Ethiopia. *J Tuberc Res Treat*. 2014;p. 753492. doi:10.1155/2014/753492.
  18. Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. *PLoS One*. 2015;10(3):e0119628. doi:10.1371/journal.pone.0119628.
  19. Okethwangu D, Birungi D, Biribawa C, Kwesiga B, Turyahabwe S, Ario AR, et al. Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment. *BMC Infect Dis J*. 2019;19(1):1–10. doi:10.1186/s12879-019-4014-3.
  20. Iacobino A, Fattorini L, Giannoni F. Drug-Resistant Tuberculosis 2020: Where We Stand. *Appl Sci*. 2020;10(6):2153. doi:10.3390/app10062153.
  21. Simbwa BN, Katamba A, Katana EB, Laker E, Nabatanzi S, Sendaula E, et al. The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study. *BMC Infect Dis*. 2021;21(950). doi:10.1186/s12879-021-06675-7.
  22. Hameed HMA, Islam M, Chhotaray C, Yew WW, Liu J, Zhang T, et al. Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR- Mycobacterium tuberculosis Strains. *Front Cell Infect Microbiol*. 2018;8:114. doi:10.3389/fcimb.2018.00114.
  23. Nguyen TNA, Anton-Le B, Bañuls AL, Nguyen TVA. Molecular Diagnosis of Drug-Resistant Tuberculosis: A Literature Review. *Front Microbiol*. 2019;10:794. doi:10.3389/fmicb.2019.00794.
  24. Charoenpak R, Santimaleworagun W, Suwanpimolkul G, Manosuthi W, Kongsanan P, Petsong S, et al. Association between the Phenotype and Genotype of Isoniazid Resistance Among Mycobacterium tuberculosis Isolates in Thailand. *J Infect Drug Resist*. 2020;13:627–34. doi:10.2147/IDR.S242261.
  25. Farnia P, Masjedi MR, Merza MA, Tabarsi P, Zhavnerko GKS, Ibrahim TA, et al. Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) tuberculosis strains: transmission and atomic force observation. *Int J Clin Exp Med*. 2010;3(4):308–14.
  26. Velayati AA, Farnia P, Masjedi MR. Totally drug-resistant tuberculosis (TDR-TB): A debate on global health communities. *Int J Mycobacteriol*. 2013;2(2):71–2. doi:10.1016/j.ijmyco.2013.04.005.
  27. Parida SK, Axelsson-Robertson R, Rao MV, Singh N, Master I, Lutckii A, et al. Totally drug-resistant tuberculosis and adjunct therapies. *J Intern Med*. 2015;277(4):388–405. doi:10.1111/joim.12264.
  28. Damtie D, Woldeyohannes D, Mathewos B. Review on Molecular mechanism of first-line antibiotic resistance in Mycobacterium tuberculosis. *Mycobact Dis*. 2014;4(6):1–4. doi:10.4172/2161-1068.1000174.
  29. Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: A review on the molecular determinants of resistance and implications for personalized care. *J Antimicrob Chemother*. 2018;73(5):1138–51. doi:10.1093/jac/dkx506.
  30. Chen CY, Weng J, Huang HH, Yen WC, Tsai YH, Cheng TC, et al. A new oligonucleotide array for the detection of multidrug and extensively drug-resistance tuberculosis. *Sci Rep*. 2019;9(1):4425. doi:10.1038/s41598-019-39339-3.
  31. Briffotiaux J, Liu S, Gicquel B. Genome-wide transcriptional responses of Mycobacterium to Antibiotics. *Front Microbiol*. 2019;10:249. doi:10.3389/fmicb.2019.00249.
  32. Eduardo P, Palomino JC. Molecular basis and mechanisms of drug-resistance in Mycobacterium tuberculosis: Classical and new drugs. *J Antimicrob Chemother*. 2011;66(7):1417–30. doi:10.1093/jac/dkr173.
  33. Gokulan K, Varughese KI. Drug-resistance in Mycobacterium tuberculosis and targeting the L, D-transpeptidase enzyme. *J Drug Dev Res*. 2018;80(1):11–8. doi:10.1002/ddr.21455.
  34. Nasiri MJ, Haeili M, Ghazi M, Goudarzi H, Pormohammad A, Fooladi AAI. New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria. *Front Microbiol*. 2017;8:681. doi:10.3389/fmicb.2017.00681.
  35. Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis: Mechanistic and evolutionary perspectives. *FEMS Microbiol Rev*. 2017;41(3):354–73. doi:10.1093/femsre/fux011.
  36. Ghajavand H, Kamakoli MK, Khanipour S, Dizaji SP, Masoumi M, Jamnani FR, et al. Scrutinizing the drug-resistance mechanism of multi- and extensively-drug resistant Mycobacterium tuberculosis: Mutations versus efflux pumps. *Antimicrob Resist Infect Control*. 2019;8:70. doi:10.1186/s13756-019-0516-4.
  37. Palomino JC, Martin A. Drug-resistance mechanisms in Mycobacterium tuberculosis. *Antibiotics (Basel)*. 2014;3(3):317–40. doi:10.3390/antibiotics3030317.
  38. Hsu LY, Lai LY, Hsieh PF, Lin TL, Lin WH, Tasi HY, et al. Two Novel katG Mutations Conferring Isoniazid Resistance in Mycobacterium tuberculosis. *Front Microbiol*. 2014;11:1644.


- doi:10.3389/fmicb.2020.01644.
39. Havumaki J, Hillemann D, Ismail N, Omar SV, Georghiou SB, Schumacher SG, et al. Comparative accuracy of the REBA MTB MDR and Hain MTBDRplus line probe assays for the detection of multidrug-resistant tuberculosis: A multi-centre, non-inferiority study. *PLoS ONE*. 2017;12(3):1–12. doi:10.1371/journal.pone.0173804.
  40. Katia PU, Fabiola CT, Beatriz SR, Mario B. Drug-resistance in Mycobacterium tuberculosis. *Intech Open Assess J*. 2018;13:118–29. doi:10.5772/intech.open.69656.
  41. Torres-Gonzalez P, Me CH, Martinez-Gamboa A, Garcia-Garcia L, Lp CH, Valle MB, et al. Human tuberculosis caused by Mycobacterium bovis: a retrospective comparison with Mycobacterium tuberculosis in a Mexican tertiary care centre. *BMC Infect Dis*. 2000;16:657. doi:10.1186/s12879-016-2001-5.
  42. Namburete EI, Tivane I, Lisboa M, Passeri M, Pocente R, Ferro JJ, et al. Drug-resistant tuberculosis in Central Mozambique: the role of a rapid genotypic susceptibility testing. *BMC Infect Dis*. 2016;16:423. doi:10.1186/s12879-016-1766-x.
  43. Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Brand J, et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insight into emergence and spread of multidrug-resistance. *Nat Genet*. 2017;49(3):395–402. doi:10.1038/ng.3767.
  44. Louw GE, Warren RM, van Pittius N, Leon R, Jimenez A, Hernandez-Pando R, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. *Am J Respir Crit Care Med*. 2011;184(2):269–76. doi:10.1164/rccm.201011-1924OC.
  45. Muthaiah M, Shivekar SS, Cuppusamy K, Alagappan C, Sakkaravarthy A, Brammachary U, et al. Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates. *J Clin Tuberc Other Mycobact Dis*. 2017;8:19–25. doi:10.1016/j.jctube.2017.06.001.
  46. Almutairi NM, Ahmad S, Mokaddas E, Eldeen HS, Joseph S. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. *BMC Infect Dis J*. 2019;19(1):3. doi:10.1186/s12879-018-3638-z.
  47. Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T, et al. Recent updates on drug- resistance in Mycobacterium tuberculosis. *J Appl Microbiol*. 2019;128(6):1547–67. doi:10.1111/jam.14478.
  48. Zaw MT, Emran NA, Lin Z. Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. *J Infect Public Health*. 2018;11(5):605–10. doi:10.1016/j.jiph.2018.04.005.
  49. Ramazanzadeh R, Mohammadi B. Mutations in embB gene associated with resistance to ethambutol in Mycobacterium tuberculosis strains isolated from TB patients in the west of Iran. *Int J Mycobacteriol*. 2016;5(1):S140. doi:10.1016/j.ijmyco.2016.11.013.
  50. Xu Y, Jia H, Huang H, Sun Z, Zhang Z. Mutations Found in embCAB, embR, and ubiA Genes of Ethambutol-Sensitive and -Resistant Mycobacterium tuberculosis Clinical Isolates from China. *J Biomed Res Int*. 2015;.
  51. Khosravi AD, Sirous M, Abdi M, Ahmadkhosravi N. Characterization of the most common embCAB gene mutations associated with ethambutol resistance in Mycobacterium tuberculosis isolates from Iran. *J Infect Drug Resist*. 2019;12:579–84. doi:10.2147/IDR.S196800.
  52. Tulyaprawat O, Chairprasert A, Chongtrakool P, Suwannakarn K, Ngam-Skulrungrroj P. Association of ubiA mutations and high-level of ethambutol resistance among Mycobacterium tuberculosis Thai clinical isolates. *J Tuberc*. 2019;114(9):42–6. doi:10.1016/j.tube.2018.11.006.
  53. Lingaraju S, Rigouts L, Gupta A, Lee J, Umubyeyi AN, Davidow AL, et al. Geographic differences in the contribution of ubiA mutations to high-level Ethambutol resistance in Mycobacterium tuberculosis. *J Antimicrob Agents Chemother*. 2016;60(7):4101–5. doi:10.1128/AAC.03002-15.
  54. Nangraj AS, Khan A, Umbreen S, Sahar S. Insights into Mutations Induced Conformational Changes and Rearrangement of Fe2+ Ion in pncA Gene of Mycobacterium tuberculosis to Decipher the Mechanism of Resistance to Pyrazinamide. *Front Mol Biosci*. 2021;8:633365. doi:10.3389/fmolb.2021.633365.
  55. Opong YEA, Phelan J, Perdigão J, Machado D, Miranda A, Viveiros M, et al. Genome-wide analysis of Mycobacterium tuberculosis polymorphisms reveals lineage-specific associations with drug resistance. *BMC Genomics*. 2019;20:252. doi:10.1186/s12864-019-5615-3.
  56. Liu Y, Gao J, Du J, Shu W, Wang L, Wang Y, et al. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. *Int J Infect Dis*. 2020;102:392–6. doi:10.1016/j.ijid.2020.10.081.
  57. Bwalya P, Yamaguchi T, Solo ES, Chizimu JY, Mbulo G, Nakajima C, et al. Characterization of Mutations associated with Streptomycin Resistance in Multidrug-Resistant Mycobacterium tuberculosis in Zambia. *Antibiotics (Basel)*. 1169;10(10):1169. doi:0.3390/antibiotics10101169.
  58. Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y, et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. *J Antimicrob Chemother*. 2015;70(9):2507–10. doi:10.1093/jac/dkv150.
  59. Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis: Implications in settings with weak healthcare systems. *Int J Infect Dis*. 2015;32:118–23. doi:10.1016/j.ijid.2015.01.006.
  60. Tiberi S, Scardigli A, Centis R, D'Ambrosio L, Muñoz-Torrico M, Salazar-Lezama M, et al. Classifying new anti-tuberculosis drugs: rationale and future perspectives. *Int J Infect Dis*. 2017;56:181–4. doi:10.1016/j.ijid.2016.10.026.
  61. Mamatha HG, Shanthi V. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a National reference laboratory in India. *J Glob Antimicrob Resist*. 2018;12:5–10. doi:10.1016/j.jgar.2017.08.014.
  62. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New insights into fluoroquinolone-resistance in Mycobacterium tuberculosis: Functional genetic analysis of gyrA and gyrB mutations. *PLoS One*. 2012;7(6):e39754. doi:10.1371/journal.pone.0039754.
  63. Catalão MJ, Filipe SR, Pimentel M. Revisiting anti-tuberculosis therapeutic Strategies that target the peptidoglycan structure and synthesis. *Front Microbiol*. 2019;10:190. doi:10.3389/fmicb.2019.00190.
  64. Desjardins CA, Cohen KA, Munsamy V, Abeel T, Maharaj K, Walker BJ, et al. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. *Nat Genet*. 2016;48(5):544–51. doi:10.1038/ng.3548.
  65. Nakatani Y, Reading H, Merker M, Machado D, Andres S, Kumar SS, et al. Role of Alanine Racemase Mutations in Mycobacterium tuberculosis d-Cycloserine Resistance. *Antimicrob Agents Chemother*. 2017;61(12):e01575–17. doi:10.1128/AAC.01575-17.
  66. Rueda J, Realpe T, Mejia I, Zapata E, Roza C, Ferro E, et al. Genotypic analysis of genes associated with independent resistance and cross-resistance to isoniazid and ethionamide in Mycobacterium tuberculosis clinical isolates. *Antimicrob Agents Chemother*. 2015;59(12):7805–10. doi:10.1128/AAC.01028-15.
  67. Machado D, Perdigao J, Ramos J, Couto I, Portugal I, Ritter C, et al. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. *J Antimicrob Chemother*. 2013;68(8):1728–32. doi:10.1093/jac/dkt090.
  68. Mugumbate G, Nyathi B, Zindoga A, Munyuki G. Application of Computational Methods in Understanding Mutations in Mycobacterium tuberculosis Drug Resistance. *Front Mol Biosci*. 2021;8:643849. doi:10.3389/fmolb.2021.643849.
  69. Islam MM, Tan Y, Hameed HMA, Liu Z, Chhotaray C, Liu Y, et al. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. *Clin Microbiol Infect*. 2018;25(8):1041.e1–e7. doi:10.1016/j.cmi.2018.12.008.



70. Vilcheze C, Jacobs WR. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. *Microbiol Spectr*. 2019;2(4):MGM2-0014–2013. doi:10.1128/microbiolspec.MGM2-0014-2013.
71. Tan Y, Su B, Zheng H, Song Y, Wang Y, Pang Y, et al. Molecular Characterization of Mycobacterium tuberculosis Isolates in Southern China. *Front Microbiol*. 2017;8:2358. doi:10.3389/fmicb.2017.02358.
72. Chen X, He G, Wang S, Lin S, Chen J, Zhang W. Evaluation of whole-genome sequence method to diagnose resistance of 13 anti-tuberculosis drugs and Characterize resistance genes in clinical multi-drug resistance Mycobacterium tuberculosis isolates from China. *Front Microbiol*. 1741;10:1741. doi:10.3389/fmicb.2019.01741.
73. Luo M, Li K, Zhang H, Yan X, Gu J, Zhang Z, et al. Molecular characterization of para-aminosalicylic acid resistant Mycobacterium tuberculosis clinical isolates in South-Western China. *J Infect Drug Resist*. 2019;12:2269–75. doi:10.2147/IDR.S207259.
74. Wei W, Yan H, Zhao J, Li H, Li Z, Guo H, et al. Multi-omics comparisons of p-aminosalicylic acid (PAS) resistance in folC mutated and un-mutated Mycobacterium tuberculosis strains. *Emerg Microbes Infect*. 2019;8(1):248–61. doi:10.1080/22221751.2019.1568179.
75. Li G, Zhang J, Jiang Y, Zhao L, Liu H, Li M, et al. Cross-resistance of isoniazid, para-aminosalicylic acid and pasiniazid against isoniazid-resistant Mycobacterium tuberculosis isolates in China. *J Glob Antimicrob Resist*. 2019;20:275–81. doi:10.1016/j.jgar.2019.08.005.
76. Pandey B, Grover S, Kaur J, Grover A. Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis. *Sci Rep*. 2019;9:13617. doi:10.1038/s41598-019-48940-5.
77. Peyclit L, Baron SA, Rolain JM. Drug repurposing to fight colistin and carbapenem-resistant bacteria. *Front Cell Infect Microbiol*. 2019;9:193. doi:10.3389/fcimb.2019.00193.
78. Karmakar M, Rodrigues CHM, Holt KE, Dunstan SJ, Denholm J, Ascher DB, et al. Empirical ways to identify novel Bedaquiline-resistance mutations in the AtpE gene. *PLoS ONE*. 2019;14(5):e0217169. doi:10.1371/journal.pone.0217169.
79. Wu S, Chan H, Hsiao H, Jou R, Adams LB. Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. *Front Microbiol*. 2021;12:754249. doi:10.3389/fmicb.2021.754249.
80. Oлару ID, Von GBF, Heyckendorf J, Yew WW, Lange C, Chang KC, et al. Novel drugs against tuberculosis: A clinician's perspective. *Eur Respir J*. 2014;45(4):1119–31. doi:10.1183/09031936.00162314.
81. Kadura S, King N, Nakhoul M, Zhu H, Theron G, Köser CU, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. *J Antimicrob Chemother*. 2020;75(8):2031–43. doi:10.1093/jac/dkaa136.
82. Angula KT, Legoabe LJ, Beteck RM. Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010 - 2020 Review. *Pharmaceuticals (Basel)*. 2021;14(5):461. doi:10.3390/ph14050461.
83. Shimokawa Y, Sasahara K, Yoda N, Mizuno K, Umehara K. Delamanid does not inhibit or induce cytochrome P450 enzymes in Vitro. *Biol Pharm Bull*. 2014;37(11):1727–35. doi:10.1248/bpb.14-00311.
84. González PJG, Perdígao J, Gomes P, Puyen ZM, Lazaro DS, Napier G, et al. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. *Sci Rep*. 2021;11(1):19431. doi:10.1038/s41598-021-98862-4.
85. Reichmuth ML, Hömke R, Zürcher K, Sander P, Avihingsanon A, Collantes J, et al. Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients. *Antimicrob Agents Chemother*. 2020;64(11):e00513–20. doi:10.1128/AAC.00513-20.
86. Sharma D, Dhuriya YK, Deo N, Bisht D. Repurposing and revival of the drugs: A new approach to combat the drug-resistant tuberculosis. *Front Microbiol*. 2017;8:452. doi:10.3389/fmicb.2017.02452.
87. Wasserman S, Louw G, Ramangoela L, Barber G, Hayes C, Omar SV, et al. Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. *J Antimicrob Chemother*. 2019;74(8):2377–84. doi:10.1093/jac/dkz206.
88. Zhang S, Chen J, Cui P, Shi W, Shi X, Niu H, et al. Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid. *Antimicrob Agents Chemother*. 2016;60(4):2542–4. doi:10.1128/AAC.02941-15.
89. Bharadwaj R. Linezolid-resistant Mycobacterium tuberculosis: Will it impact the tuberculosis elimination programme? *Indian J Med Respir*. 2021;154(1):16–8. doi:10.4103/ijmr.IJMR\_3537\_20.
90. Duan H, Chen X, Li Z, Pang Y, Jing W, Liu P, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. *J Clin Microbiol Infect*. 2019;25(2):128–30. doi:10.1016/j.cmi.2018.07.012.
91. Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y, et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. *J Antimicrob Chemother*. 2015;70(9):2507–10. doi:10.1093/jac/dkv150.
92. Hartkoon RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. *Antimicrob Agents Chemother*. 2014;58(5):2979–81. doi:10.1128/AAC.00037-14.
93. Chetty S, Ramesh M, Pillay AS, Soliman MES. Recent advancements in the development of anti-tuberculosis drugs. *Bioorg Med Chem Lett*. 2017;27(3):370–86. doi:10.1016/j.bmcl.2016.11.084.
94. Mcneil MB, O'Malley T, Dennison D, Shelton CD, Sunde B, Parish T, et al. Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors. *mSphere*. 2020;5(5):e00985–20. doi:10.1128/mSphere.00985-20.

## Author biography

**David Kajoba Mumena**, Post Graduate Student  <https://orcid.org/0000-0002-8137-8421>

**Geoffrey Kwenda**, Professor, Senior Lecturer & Researcher  <https://orcid.org/0000-0003-0151-8883>

**Caroline Wangari Ngugi**, Chairperson, Lecturer & Researcher  <https://orcid.org/0000-0002-0998-8217>

**Andrew Kimang'a Nyerere**, Former Chairman, Lecturer & Researcher  <https://orcid.org/0000-0002-7894-6643>

**Cite this article:** Mumena DK, Kwenda G, Ngugi CW, Nyerere AK. Drug-target genes and their spontaneous mutations associated with resistance to first-line, second-line, third-line, novel and repurposed anti-tuberculosis drugs in Mycobacterium tuberculosis resistant strains. *IP Int J Med Microbiol Trop Dis* 2022;8(3):196-204.